Novavax said on Tuesday it signed a licensing ​agreement allowing Pfizer access to its technology that boosts immune ...

Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...

Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M. Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market ...

Recent health sector developments highlight Moderna and Merck's promising skin cancer vaccine trial alongside China's declining birthrate, and significant business moves from pharmaceuticals giants ...

Novavax (NASDAQ:NVAX) got a lift early Tuesday after the vaccine maker landed a licensing deal with Pfizer that puts its ...

Most people won't experience allergic reactions to the vaccine, experts insist. The Food and Drug Administration late Friday authorized Pfizer's COVID-19 vaccine for people ages 16 and up, but warned ...